Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status
暂无分享,去创建一个
J. Heymach | M. Hellmann | M. Nishino | F. Hong | P. Sawan | B. Carter | H. Rizvi | M. Awad | E. Aguilar | A. Plodkowski | M. Altan | Jia Luo | B. Ricciuti | J. Alessi | Zihan Wei | E. Jiménez-Aguilar | J. Heymach
[1] L. Billingham,et al. Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial. , 2020, The Lancet Respiratory Medicine.
[2] J. Milanowski,et al. CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations. , 2020, European journal of cancer.
[3] H. Groen,et al. OA04.02 CheckMate 817: First-Line Nivolumab + Ipilimumab in Patients with ECOG PS 2 and Other Special Populations with Advanced NSCLC , 2019, Journal of Thoracic Oncology.
[4] L. Einhorn,et al. Safety, Efficacy, and Patient-reported Health-related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged ≥70 Years or with Poor Performance Status (CheckMate 153). , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[5] N. Reinmuth,et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. , 2019, The Lancet. Oncology.
[6] Jianying Zhou,et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial , 2019, The Lancet.
[7] B. Gyawali,et al. Immunotherapy in Non-Small-Cell Lung Cancer Patients With Performance Status 2: Clinical Decision Making With Scant Evidence. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] A. Tafreshi,et al. Pembrolizumab plus Chemotherapy for Squamous Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.
[9] Federico Cappuzzo,et al. Atezolizumab for First‐Line Treatment of Metastatic Nonsquamous NSCLC , 2018, The New England journal of medicine.
[10] S. Novello,et al. Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.
[11] Y. Shentu,et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.
[12] A. Bleyer,et al. The Role of Clinical Trial Participation in Cancer Research: Barriers, Evidence, and Strategies. , 2016, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[13] C. Barrios,et al. Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Xianghua Luo,et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] David W. Hosmer,et al. Applied Survival Analysis: Regression Modeling of Time-to-Event Data , 2008 .
[16] J. Cashy,et al. Prevalence of Poor Performance Status in Lung Cancer Patients: Implications for Research , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[17] C. Obasaju,et al. P2-292: A randomized Phase 3 trial of gemcitabine with or without carboplatin in performance status 2 (PS2) patients with advanced (stage IIIB with pleural effusion or IV) non-small-cell lung cancer (NSCLC) , 2007 .
[18] David Harrington,et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.